Ekso Bionics (NASDAQ:EKSO) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com assumed coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research note issued to investors on Thursday. The brokerage set a “hold” rating on the stock.

A number of other brokerages have also issued reports on EKSO. HC Wainwright dropped their price target on shares of Ekso Bionics from $10.00 to $9.00 and set a “buy” rating for the company in a research note on Tuesday, October 29th. Lake Street Capital reduced their price target on shares of Ekso Bionics from $2.50 to $2.00 and set a “buy” rating on the stock in a research report on Tuesday, October 29th.

Ekso Bionics Stock Performance

NASDAQ EKSO opened at $0.70 on Thursday. Ekso Bionics has a 1-year low of $0.66 and a 1-year high of $3.13. The business’s 50-day simple moving average is $0.91 and its 200-day simple moving average is $1.05. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.81 and a quick ratio of 2.14. The firm has a market capitalization of $15.38 million, a P/E ratio of -1.08 and a beta of 1.43.

Ekso Bionics (NASDAQ:EKSO) last announced its earnings results on Monday, October 28th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.02). The company had revenue of $4.13 million for the quarter, compared to analysts’ expectations of $6.00 million. Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. During the same quarter in the previous year, the business posted ($0.24) earnings per share. Equities analysts predict that Ekso Bionics will post -0.48 EPS for the current year.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.